Peptide for skin regeneration or wound treatment and use thereof

ABSTRACT

Provided is a novel peptide for skin regeneration or wound healing and a use thereof. The novel peptide not only promotes the wound healing by increasing the production amount of collagen in dermal fibroblasts but also has an excellent whitening effect by inhibiting the production amount of melanin and tyrosinase activity of melanoma cells, and consists of peptides having a very small size to minimize side effects according to administration of external substances of very small peptides. As a result, it is expected that the novel peptide can be used as an active substance that can replace existing skin regeneration or would therapeutic agents.

CROSS-REFERENCE TO RELATED APPLICATIONS

The instant application is a continuation-in-part of U.S. patentapplication Ser. No. 15/739,894 filed on Dec. 26, 2017, which is anational-stage application under 35 USC § 371 of international patentapplication No. PCT/KR2017/002998 filed on Mar. 21, 2017, and claims thepriority to Korean patent application No. 10-2016-0034327 filed on Mar.23, 2016, and the entire disclosures of the prior-filed applications areincorporated herein by reference.

TECHNICAL FIELD

The present invention relates to a peptide for skin regeneration orwound healing and a use thereof.

The present invention is achieved by the project number of 1711030975under the support of the governmental department in Korea, the researchmanagement organization of the project is the Korea Research Foundation,the name of the research business is the discovery business of creativematerials, the name of the research project is the development ofbiodegradable skin regeneration material based on the functional immunetechnology, and the research period is from Dec. 4, 2015 to Apr. 30,2016.

BACKGROUND ART

The skin is a primary barrier of the human body and protects the organsin the body from stimulation caused by external environments such as atemperature, a change in humidity, ultraviolet rays, pollutants, andplays an important role in maintaining homeostasis such as regulation ofbody temperature. The keratin, which is located at the outermost part ofthe skin, is a tissue formed by a change in cells of the skin, andconsists of completely dead cells. Coarse cell layers formed in thedermal connective tissue of the dermis have no vitality of cells towardthe epidermis and are changed into solid and regular cell layers. Theskin with this structure serves as a line of defense that protects themoisture of the body from the outermost side and defends the varioussubstances input from outside. That is, when the surface of the skin iswounded, the rapid regenerating ability of the epidermis promotes therecovery of the wound, thereby preventing additional infection throughthe wound and reducing the scarring of the skin surface.

When the damaged skin tissue is reconstructed, various reactions areinvolved, and particularly, migration, proliferation, anddifferentiation of keratinocytes, detachment of damaged cells, andproduction of the epithelial tissue are involved. The process of woundhealing is a very complex reaction involving various cells and factors,and first, the platelet is aggregated at the wound site and various cellproliferation factors such as a transfection factor, a platelet-derivedproliferative factor, and an epithelial cell proliferative factor arereleased to stimulate vascular endothelium, phagocyte, fibroblast andepithelial cells, thereby promoting cell proliferation. At the sametime, while these cells themselves self-secretively produce and secretesubstances such as fibroblast proliferation, transforming growthfactors, interleukin and other substances, the wound healing mechanismproceeds.

Currently, an epidermal growth factor (EGF), which is widely used as awound therapeutic agent due to various activities, is either obtained bypurification or obtained by overexpression in bacteria. It takes a lotof time, money, and labor to obtain by direct purification. Also, theover-expression method in the bacteria has a problem in that therecovery yield is very low due to the low expression level in the cellsand proteolytic enzyme of the bacteria. In addition, the EGF has beenreported to exhibit a low therapeutic effect on chronic wound sites, andit has been difficult to commercialize the EGF due to the high price tothe efficiency due to a temperature and a short half-life due to theproteolytic enzyme.

Under such a background, development of a novel therapeutic agent havingan effective therapeutic effect while minimizing side effects ofconventional drugs for skin regeneration or wound healing has beenrequired and has been actively studied (Korean Patent Publication No.10-2015-0135743), but it is still not enough.

DISCLOSURE Technical Problem

The present invention has been made in an effort to solve the aboveproblems, and the present inventors have made intensive studies onformulations for skin generation or wound healing to prepare a peptideconsisting of 15 amino acids or less and confirmed enhancement of theproduction amount of collagen of dermal fibroblasts, the productionamount of melanin of melanoma cells and a tyrosinase activity inhibitioneffect when the peptide was treated, and completed the present inventionbased thereon.

An object of the present invention is to provide a peptide for skinregeneration or wound healing, consisting of amino acid represented bySEQ ID NO: 1 or 2.

Another object of the present invention is to provide a pharmaceuticalcomposition for skin regeneration or wound healing, containing thepeptide or a polynucleotide encoding the peptide as an activeingredient.

Yet another object of the present invention is to provide a healthfunctional food/cosmetic composition for skin regeneration or woundhealing, containing the peptide as an active ingredient.

However, technical objects of the present invention are not limited tothe aforementioned purpose and other objects which are not mentioned maybe clearly understood to those skilled in the art from the followingdescription.

Technical Solution

In order to achieve the object, in one aspect, the present inventionprovides a peptide consisting of amino acid represented by SEQ ID NO: 1or 2. The peptide may be synthetically produced.

In a preferred embodiment, an N- or C-terminal of the peptide may bindto a protective group which is selected from the group consisting of anacetyl group, a fluorenylmethoxy carbonyl group, a formyl group, apalmitoyl group, a myristyl group, a stearyl group, a polyethyleneglycol (PEG) group, a methyl group, D-form peptide group, an amidegroup, an albumin group, a polysialic acid (PSA) group, a hydroxyethylstarch (HES) group, and a C12-C18 fatty acid group.

In another aspect, the present invention provides a pharmaceuticalcomposition for skin regeneration or wound healing, containing thepeptide or a polynucleotide encoding the peptide as an activeingredient.

In a preferred embodiment, the peptide may be contained at aconcentration of 1 to 500 ng/ml.

In another preferred embodiment, the wound may be a gash.

In still another preferred embodiment, the composition may furtherinclude a pharmaceutically acceptable carrier.

In yet another aspect, the present invention provides a cosmeticcomposition for improving skin aging or wound, containing the peptide asan active ingredient.

In a preferred embodiment, the composition may be in the form ofsuspension, emulsion, paste, gel, cream, lotion, powder, wax or spray.

In another preferred embodiment, the composition may have a skinwhitening activity.

In still another aspect, the present invention provides a method forskin regeneration or wound healing including administering the peptideto a subject.

In still yet another aspect, the present invention provides a use forskin regeneration or wound healing of the peptide.

Advantageous Effects

The novel peptide according to the present invention not only promotesthe wound healing by increasing the production amount of collagen indermal fibroblasts but also has an excellent whitening effect byinhibiting the production amount of melanin and tyrosinase activity ofmelanoma cells, and consists of peptides having a very small size tominimize side effects according to administration of external substancesof very small peptides. As a result, it is expected that the novelpeptide can be used as an active substance that can replace existingskin regeneration or would therapeutic agents.

DESCRIPTION OF DRAWINGS

FIG. 1 illustrates a result of measuring an amount of procollagenproduced from human dermal fibroblasts according to treatment of peptide1 of the present invention.

FIG. 2 illustrates a result of measuring an amount of Col1A1 producedfrom human dermal fibroblasts according to treatment of peptide 1 of thepresent invention.

FIG. 3 illustrates a result of measuring an amount of melanin producedfrom melanoma cells according to treatment of peptide 1 of the presentinvention.

FIG. 4 illustrates a result of evaluating tyrosinase activity ofmelanoma cells according to treatment of peptide 1 of the presentinvention.

FIG. 5 illustrates a result of confirming a wound healing effect in anin vitro wound model according to treatment of peptide 1 of the presentinvention.

FIG. 6 illustrates a result of confirming a wound healing effect in anin vitro wound model according to treatment of peptide 2 of the presentinvention.

FIG. 7 illustrates a result of quantifying and evaluating a woundhealing effect in an in vitro wound model according to treatment ofpeptide 1 of the present invention.

FIG. 8 illustrates a result of quantifying and evaluating a woundhealing effect in an in vitro wound model according to treatment ofpeptide 2 of the present invention.

FIG. 9 illustrates a result of confirming a wound healing effect in anacute cut animal model according to treatment of peptide 1 or 2 of thepresent invention.

FIG. 10 illustrates a result of quantifying and evaluating a woundhealing effect in an acute cut animal model according to treatment ofpeptide 1 or 2 of the present invention.

FIG. 11 illustrates a result of confirming a skin tissue change throughH&E staining in an acute cut animal model according to treatment ofpeptide 1 or 2 of the present invention.

MODES OF THE INVENTION

Hereinafter, the present invention will be described in detail.

The present invention provides a peptide consisting of amino acidrepresented by SEQ ID NO: 1 or 2.

In the present invention, the “peptide” refers to a polymer consistingof two or more amino acids linked by an amide bond (alternatively, apeptide bond) and refers to a peptide having skin regeneration or woundhealing activity for the purpose of the present invention. Despitevarious studies on a peptide therapeutic agent, there is a disadvantagethat the peptide is too large in self-size to effectively introducetarget tissues or cells, or has a short half-life and disappears in thebody in a short period. As a result, the present invention has atechnical meaning in that a novel peptide consisting of 20 amino acidsor less while having an effective therapeutic effect is firstestablished.

The peptide of the present invention may consist of amino acidrepresented by SEQ ID NO: 1 or 2, and may include an amino acid sequencehaving sequence homology with the amino acid sequence represented by SEQID NO: 1 or 2 of 75% or more, preferably 80% or more, more preferably90% or more and most preferably 95% or more, and may additionallyinclude an amino acid sequence prepared for the specific purpose ofincreasing a targeting sequence, a tag, a labeled residue, half-life, orpeptide stability.

Further, the peptide may include a functional variant for the peptide ofthe present invention. The functional variant includes biologicalequivalents of a peptide sequence (SEQ ID NOS: 1 or 2) disclosed in thepresent specification. For example, additional modifications in aminoacid or polynucleotide sequence of the peptide may be made to furtherimprove the binding affinity and/or other biological properties of thepeptide. Such modifications include deletion, insertion, and/orsubstitution of amino acid sequence residues of the peptide and areperformed based on the relative similarity of amino acid side chainsubstituents, for example, hydrophobicity, hydrophilicity, charge size,and the like. By analysis of the size, shape and type of amino acid sidechain substituents, it can be seen that arginine, lysine and histidineare all positively charged residues; alanine, glycine and serine havesimilar sizes; and phenylalanine, tryptophan and tyrosine have similarshapes. Accordingly, based on these considerations, arginine, lysine andhistidine; alanine, glycine and serine; and phenylalanine, tryptophanand tyrosine may refer to biologically functional equivalents.

In addition, the peptide of the present invention may be obtained byvarious methods well known in the art. For example, the peptide may beprepared by polynucleotide recombination and protein expression systemsor synthesis in vitro through chemical synthesis such as peptidesynthesis, and cell-free protein synthesis.

In addition, to obtain better chemical stability, enhancedpharmacological properties (half-life, absorbency, potency, efficacy,etc.), altered specificity (e.g., broad biological activity spectrum),and reduced antigenicity, a protective group may bind to an N- orC-terminal of the peptide. Preferably, the protective group may be anacetyl group, a fluorenylmethoxycarbonyl group, a formyl group, apalmitoyl group, a myristyl group, a stearyl group, a polyethyleneglycol (PEG) group, a methyl group, D-form peptide group, an amidegroup, an albumin group, a polysialic acid (PSA) group, a hydroxyethylstarch (HES) group, or a C12-C18 fatty acid group, but may include anyingredient capable of enhancing modification of the peptide,particularly, stability of the peptide, without limitation. The term“stability” used in the present invention refers to storage stability(for example, room-temperature storage stability) as well as in-vivostability that protects the peptide of the present invention from attackof a protein cleavage enzyme in vivo.

In the present invention, “polynucleotide” is a polymer to which anucleotide binds, and serves to transmit genetic information. For thepurpose of the present invention, the polynucleotide encodes the peptideof SEQ ID NO: 1 or 2 and may include a polynucleotide sequence encodingthe peptide and a sequence having sequence homology of 75% or more,preferably 85% or more, more preferably 90% or more, and most preferably75% or more.

The term “homology” used in the present invention is to indicate asimilar degree to a wide-type amino acid sequence or a polynucleotidesequence, and the comparison of the homology may be performed using acomparison program which is well-known in the art and homology betweenat least two sequences may be calculated by a percentage (%).

In another aspect, the present invention provides a pharmaceuticalcomposition for skin regeneration or wound healing, containing thepeptide or a polynucleotide encoding the peptide as an activeingredient; a use for skin regeneration or wound healing of the peptide;and a method for skin regeneration or wound healing includingadministering a therapeutically effective dose of peptide to a subject.

The term “treatment” used in the present invention means all actions forimproving or beneficially changing symptoms for the wound byadministering the pharmaceutical composition according to the presentinvention.

In the present invention, the “subject” refers to a subject requiringtreatment of the wound, and more specifically, refers to human ornon-human primates, and mammals such as mice, dogs, cats, horses, andcows.

The term “skin regeneration” used in the present invention refers to aseries of reactions in which a skin tissue is reconstituted in responseto an overall skin aging and an external stimulus induced in the skin,and as one example, exhibits skin whitening, skin elasticityimprovement, and wrinkle improvement effects. The “skin whitening”refers to not only brightening skin tone by inhibiting the synthesis ofa melanin pigment but also improving skin hyperpigmentation such asspots or freckles caused due to ultraviolet rays, hormones or heredity.

The term “wound” used in the present invention refers to a phenomenon inwhich the tissues are damaged by external stimuli and general woundhealing is usually accompanied by processes such as degeneration anddeath of cells, planocytes from surrounding tissues, effusion of tissueliquids, and precipitation of fibrin and formation of granulationtissue. For the purpose of the present invention, the wound treatmentrefers to helping reconstitution into normal skin tissue by promotingthe processes as described above. Meanwhile, the wound may preferably bea gash, but is not limited thereto.

According to one embodiment of the present invention, two kinds ofpeptides (peptide 1 and peptide 2) were prepared (see Example 1), and bytreating the peptide, a production amount of collagen is increased topromote wound healing and melanin production and tyrosinase activity ofa B16F10 melanoma cell line were inhibited to confirm an excellentwhitening effect (see Examples 2 to 4). In addition, by using a scratchassay and an acute cut animal model to evaluate the migration ability ofHaCaT cells, an excellent wound treatment effect (reduction of wound) ofthe peptide can be confirmed (see Examples 5 and 6), and the peptide maybe widely used as an active substance and a skin whitening agent whichcan replace existing formulations for skin regeneration or woundhealing.

Meanwhile, the peptide or the polynucleotide encoding the peptide of thepresent invention may be delivered to a pharmaceutically acceptablecarrier such as a colloidal suspension, powder, saline, lipid, liposome,microspheres, or nanospheric particles. The peptide or thepolynucleotide may form a complex with a carrier or associated with thecarrier and may be delivered in vivo using a delivery system which isknown in the art, such as lipids, liposomes, microparticles, gold,nanoparticles, polymers, condensation reagents, polysaccharides,polyamino acids, dendrimers, saponins, adsorption enhancers or fattyacids.

In addition, the pharmaceutically acceptable carrier includes lactose,dextrose, sucrose, sorbitol, mannitol, starch, acacia, rubber, calciumphosphate, alginate, gelatin, calcium silicate, microcrystallinecellulose, polyvinylpyrrolidone, cellulose, water, syrup,methylcellulose, hydroxybenzoate, propylhydroxybenzoate, talc, magnesiumstearate, mineral oil, and the like, which are generally used informulation, but is not limited thereto. Further, the pharmaceuticalcomposition may further include lubricants, wetting agents, sweeteners,flavors, emulsifiers, suspensions, preservatives, and the like inaddition to the ingredients.

For the purpose of the present invention, the pharmaceutical compositionof the present invention may preferably contain the peptide of thepresent invention at a concentration of 1 to 500 ng/ml for the skinregeneration effect, but is not limited thereto as long as theconcentration may predict an effective therapeutic effect withoutcytotoxicity.

The pharmaceutical composition of the present invention may beadministered orally or parenterally (for example, intramuscularly,intravenously, intraperitoneally, subcutaneously, intradermally, ortopically) depending on the intended method, and the dose variesaccording to the condition and weight of a patient, the degree ofdisease, a type of drug, and the route and time of administration, butmay be suitably selected by those skilled in the art.

Particularly, in the case of using the pharmaceutical composition of thepresent invention as an dermal external preparation, the pharmaceuticalcomposition may additionally contain an adjuvant which is commonly usedin a dermatology field, such as any other ingredient commonly used inthe dermal external preparation including a fatty substance, an organicsolvent, a solubilizer, a thickener and a gelling agent, a softener, anantioxidant, a suspending agent, a stabilizer, a foaming agent, aperfume, a surfactant, water, an ionic emulsifier, a nonionicemulsifier, a filler, a sequestering agent, a chelating agent, apreservative, vitamins, a blocking agent, a wetting agent, essentialoil, a dye, a pigment, a hydrophilic active agent, a lipophilic activeagent or a lipid vesicle. Further, the ingredients may be introducedwith amounts commonly used in the dermatology field. In addition, thepharmaceutical composition is provided as the dermal externalpreparation, but is not limited thereto, and may be a formulation, suchas an ointment, a patch, a gel, a cream or a spray.

The pharmaceutical composition of the present invention is administeredwith a pharmaceutically effective dose. In the present invention, the“pharmaceutically effective dose” means a amount which is sufficient totreat the diseases at a reasonable benefit/risk ratio applicable tomedical treatment, and an effective dose level may be determinedaccording to elements including a kind of disease of the patient, theseverity, activity of a drug, sensitivity to a drug, a time ofadministration, a pathway of administration, and an emission rate,duration of treatment, and simultaneously used drugs and other elementswell-known in the medical field. The pharmaceutical compositionaccording to the present invention may be administered as an individualtherapeutic agent or in combination with other therapeutic agents,simultaneously, separately or sequentially administered with existingtherapeutic agents, and administered singly or multiply. It is importantto administer an amount capable of obtaining a maximum effect with aminimal amount without side effects by considering all of the elementsand the amount may be easily determined by those skilled in the art.

In particular, the effective dose of the pharmaceutical compositionaccording to the present invention may vary according to age, gender,condition, and weight of the patient, absorption of active ingredientsin the body, inactive rate, excretion rate, disease type, and combineddrugs, and may be increased or decreased according to the route ofadministration, the severity of obesity, gender, weight, age, and thelike.

Further, in yet another aspect, the present invention provides a healthfunctional food/cosmetic composition for improving skin aging or wound,containing the peptide or a polynucleotide encoding the peptide as anactive ingredient.

The term “improvement” used in the present invention means all actionsthat at least reduce parameters associated with a treated condition, forexample, the degree of symptoms. At this time, the health functionalfood/cosmetic composition may be used simultaneously or separately withthe drug for treatment before or after the onset of the related diseasesfor preventing or improving skin aging or wound.

In the health functional food composition of the present invention, theactive ingredient may be added to the food as it is or may be usedtogether with other food or food ingredients, and may be appropriatelyused according to general methods. A mixing amount of the activeingredients may be appropriately determined according to a purpose ofuse (for prevention or improvement) thereof. Generally, in preparationof foods or beverages, the composition of the present invention may beadded with an amount of preferably 15 wt % or less and more preferably10 wt % or less with respect to a raw material. However, in the case oflong-term ingestion for the purpose of health and hygiene or healthregulation, the amount may be below the above range.

The health functional food composition of the present invention maycontain other ingredients as a required ingredient without specificlimitation other than the active ingredient. For example, like a generalbeverage, various flavoring agents or natural carbohydrates may be addedas an additional ingredient. Examples of the aforementioned naturalcarbohydrates include general sugars, such as monosaccharides, forexample, glucose, fructose, and the like; disaccharides, for example,maltose, sucrose, and the like; and polysaccharides, for example,dextrin, cyclodextrin, and the like, and sugar alcohols, such asxylitol, sorbitol, and erythritol. As the flavoring agents other thanthe above examples, natural flavoring agents (thaumatin and steviaextract (e.g., rebaudioside A, glycyrrhizin, etc.) and syntheticflavoring agents (saccharin, aspartame, etc.) may be advantageouslyused. The ratio of the natural carbohydrate may be appropriatelydetermined by selection of those skilled in the art.

In addition, the health food composition according to the presentinvention may contain various nutrients, vitamins, minerals(electrolytes), flavoring agents such as synthetic flavoring agents andnatural flavoring agents, coloring agents and thickening agents (cheese,chocolate, etc.), pectic acid and salts thereof, alginic acid and saltsthereof, organic acid, a protective colloidal thickener, a pH adjustingagent, a stabilizer, a preservative, glycerin, alcohol, a carbonic acidagent used in a carbonated drink, and the like. These ingredients may beused independently or in combination, and the ratio of such additivesmay also be appropriately selected by those skilled in the art.

The cosmetic composition of the present invention may be prepared by anyformulation which is generally prepared in the art and for example, maybe formulated by a solution, a suspension, an emulsion, paste, gel,cream, lotion, powder, soap, a surfactant-containing cleanser, oil,powder foundation, emulsion foundation, wax foundation, spray and thelike, but is not limited thereto. More particularly, the cosmeticcomposition of the present invention may be prepared by a formulation ofemulsion lotion, nutrition lotion, nourishing cream, massage cream,essence, eye cream, cleansing cream, cleansing foam, cleansing water,pack, spray or powder.

The effective carrier contained in the cosmetic composition of thepresent invention may use a carrier which is generally used in the artdepending on the formulation. When the formulation of the presentinvention is paste, cream, or gel, as a carrier ingredient, animal oil,vegetable oil, waxes, paraffins, starch, tragacanth, cellulosederivatives, polyethylene glycol, silicone, bentonite, silica, talc,zinc oxide, or the like may be used.

When the formulation of the present invention is the powder or thespray, as the carrier ingredient, lactose, talc, silica, aluminumhydroxide, calcium silicate, or polyamide powder may be used.Particularly, in the case of the spray, a propellant such aschlorofluoro hydrocarbon, propane/butane or dimethyl ether may beadditionally included.

When the formulation of the present invention is the solution or theemulsion, as the carrier ingredient, a solvent, a dissolving agent, oran emulsifying agent is used, and for example, water, ethanol,isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzylbenzoate, propylene glycol, 1,3-butyl glycol oil, glycerol aliphaticester, polyethylene glycol, or sorbitan fatty acid ester is included.

When the formulation of the present invention is the suspension, as thecarrier ingredient, a liquid diluent such as water, ethanol, orpropylene glycol, a suspension such as ethoxylated isostearyl alcohol,polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester,microcrystalline cellulose, aluminum metahydroxide, bentonite, agaroseor tragacanth may be used.

When the formulation of the present invention is thesurfactant-containing cleanser, as the carrier ingredient, aliphaticalcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinatemonoester, isethionate, imidazolinium derivatives, methyl taurate,sarcosinate, fatty acid amide ether sulfate, alkyl amido betaine,aliphatic alcohol, fatty acid glyceride, fatty acid diethanolamide,vegetable oil, lanoline derivatives, ethoxylated glycerol fatty acidester, or the like may be used.

The ingredients contained in the cosmetic composition of the presentinvention may contain ingredients which are generally used in thecosmetic composition in addition to the active ingredients and thecarrier ingredients, and for example, may contain general adjuvants suchas antioxidants, stabilizers, solubilizers, vitamins, pigments andfragrances.

Hereinafter, preferred Examples for helping in understanding of thepresent invention are proposed. However, the following Examples areprovided for more easily understanding the present invention and thecontents of the present invention are not limited by the followingExamples.

EXAMPLES Example 1. Preparation of Peptide

In Example 1, peptides in Table 1 below were prepared. Thereafter, thesynthesized peptides were purified using a high-performance liquidchromatography (SHIMADZU Prominence HPLC) and a column used a Shiseidocapcell pak C18 column (4.6×50 mm). Further, the mass of the synthesizedpeptide was confirmed using a mass spectrometer (HP 1100 series LC/MSD).

TABLE 1 Number Amino acid sequence 1 REGRT (SEQ. 1) 2REGRTREGRT (SEQ. 2)

Example 2. Evaluation of Production Ability of Collagen of Human DermalFibroblasts

Collagen is a main ingredient of skin connective tissues, and increasedcollagen expression is essential in wound healing such as a gash or skinregeneration. As a result, in Example 2, the production ability ofcollagen of human dermal fibroblasts (HDF) according to the treatment ofthe peptide (peptide 1) prepared in Example 1 was evaluated by anexperimental method disclosed in the existing document (J. Biol. Chem.1993 268(14): 9941-9944). First, the human dermal fibroblasts werecultured in a DMEM medium added with 10% fetal bovine albumin (FBS), andthe cultured cells were divided into a 6-well plate at a concentrationof 2×10⁵ cell/well and cultured for 24 hours, and then the medium wasreplaced with 2% FBS. After 24 hours from this, the cells were treatedwith the peptide (100, 10, 1 ng/ml) of the present invention, andthereafter, an amount of procollagen secreted to the culture medium wasmeasured by using a Procollagen Type I C-peptide (PIP) EIA Kit, RNA wasextracted with a Trizol reagent, and then the expression of Col1A1(collagen type I, alpha 1) mRNA of the human dermal fibroblasts wasconfirmed through real-time PCR. Meanwhile, a separately untreated group(Control) was used as a control group and a TGF-treated group (TGF-) wasused as a positive control group.

As a result, as illustrated in FIGS. 1 and 2, it could be seen that inthe group treated with the peptide of the present invention, a secretionamount of procollagen was increased compared to the control group andthe TGF-treated group, and the expression of Col1A1 was significantlyincreased at a concentration of 10 ng/ml or more. From the result, itcould be seen that the peptide of the present invention induced thegeneration of collagen to contribute to promotion of skin generation orwound healing.

Example 3. Evaluation of Production Ability of Melanin of Melanoma Cells

The color of the skin is determined by an amount of melanin pigmentproduced by melanoma cells, and many studies have been conducted toimprove abnormal pigmentation of the skin. Particularly, excessivepigmentation caused by chronic gashes is considered as a major medicalproblem, but no definitive treatment method has yet been developed.Thus, in Example 2, the production ability of melanin of a melanoma cellline according to the treatment of the peptide (peptide 1) prepared inExample 1 was evaluated by an experimental method disclosed in theexisting document (Life Sci. 2013 Aug. 14; 93(5-6):226-32). The melanomacell line, B16F10 cells, was cultured in a DMEM medium added with 10%fetal bovine albumin, and the cultured cells were divided into a 12well-plate at a concentration of 1×10⁵ cells/well. After the culture for24 hours, α-MSH (10 uM) promoting melanin synthesis and the peptide (1,10, and 100 ng/ml) of the present invention were treated and culturedagain for 24 hours, added with 200 μl of a 1N NaOH solution afterwashing each well with PBS, and then dissolved at 100° C. for 30minutes. Thereafter, the absorbance was measured at 405 nm with an ELISAreader to confirm the amount of melanin produced from the melanoma cellline. Meanwhile, an untreated group was used as a control group and aα-MSH-treated group was used as a positive control group.

As a result, as illustrated in FIG. 3, a large amount of melanin wasproduced from the melanoma cell line in the α-MSH-treated group, whereasthe production amount of melanin was greatly reduced in the grouptreated with the peptide of the present invention and particularly,there was no significant difference from a non-α-MSH-treated group. Fromthe result, it could be seen that the peptide of the present inventionhad a skin whitening effect according to inhibition of melaninproduction.

Example 4. Evaluation of Tyrosinase Activity of Melanoma Cells

Tyrosinase as a rate-regulating enzyme that catalyzes the reaction inthe melanin biosynthesis process was known to play a crucial role inregulating the amount of melanin in the cells. Thus, in Example 4, thetyrosinase activity of the melanoma cell line according to the treatmentof the peptide (peptide 1) prepared in Example 1 was evaluated by anexperimental method disclosed in the existing document (J. Dermatol.Sci. Vol. 57 (2010) 170-177). The melanoma cell line, B16F10 cells, wasdivided into a 12 well-plate at a concentration of 1×10⁵ cells/well andcultured for 24 hours, and then treated with α-MSH (1M) and the peptideof the present invention (1, 10, 100 ng/ml), cultured for 24 hoursagain, and then was washed with PBS and suspended in a 50 mM phosphatebuffer (pH 6.8) containing 1% Triton X-100 after washing each well withPBS. After vortexing, the cells was frozen at 80° C. for 30 minutes,dissolved at room temperature, and centrifuged at 1000 g for 10 minutes,and then 40 μl of a supernatant and 100 μl of 10 mM L-DOPA were added toa 96 well-plate and reacted at 37° C. Thereafter, the absorbance wasmeasured at 405 nm with an ELISA reader to confirm the tyrosinaseactivity of the melanoma cell line. Meanwhile, a separate untreatedgroup was used as a control group and a α-MSH-treated group and a Kojicacid-treated group were used as a positive control group.

As a result, as illustrated in FIG. 4, the tyrosinase activity of themelanoma cell line was greatly increased in the α-MSH-treated group,whereas the enzyme activity was greatly reduced in the group treatedwith the peptide of the present invention and there was no significantdifference from the Kojic acid-treated group having tyrosinaseinhibition activity. From the result, it could be seen that the peptideof the present invention had a skin whitening effect according toinhibition of tyrosinase activity.

Example 5. Confirmation of Wound Treatment Effect Using In Vitro WoundHealing Model

In Example 5, the wound treatment effect according to the treatment ofthe peptides (peptides 1 and 2) prepared in Example 1 was confirmedthrough a scratch assay. A human epithelial cell line, HaCaT cells wascultured for 2 hours by adding Mitomycin C (10 ug/ml) in a serum-freemedium to induce scratch wound. After the cells were treated with thepeptide (1 or 10 ng/ml) and TGF-β (1 ng/ml) as a positive control groupin a medium added with 10% FBS, the migration ability of cells wasobserved over time and the reduction in wound size was quantified.

As a result, as illustrated in FIGS. 5 and 6, it was confirmed that themigration of HaCaT cells was increased in a peptideconcentration-dependent manner in the group treated with the peptide ofthe present invention. Further, as the result of quantifying andevaluating the wound size, as illustrated in FIGS. 7 and 8, significantreduction of the wound size according to treatment of peptide 1 orpeptide 2 was confirmed, and particularly, the effect of peptide 2 wasmore remarkable and a definite wound reduction effect was observed evenat a relatively low concentration (1 ng/ml) as well as a highconcentration (10 ng/ml).

Example 6. Confirmation of Wound Treatment Effect Using Acute WoundAnimal Model

In Example 6, the wound treatment effect according to the treatment ofthe peptides (peptides 1 and 2) prepared in Example 1 was confirmed invivo using an acute wound animal model.

6-1. Confirmation of Change in Wound Size

After an 8-week-old Balb/c nude mouse was anesthetized with Avertin(2.5%), the skin of the animal's back was cut by using a circular punchhaving a 10 mm diameter to induce an acute wound. The peptide wastreated (500 ng/one time) at the site of excision total 5 times at24-hour intervals at the site of excision and reduction of the woundarea over time was measured for 14 days and an EGF was used as apositive control group (10 ug/one time). In this case, the peptide wastreated with 20% pluronic F-127 (PBS) in a mixture state and the woundsizes over time were measured and digitized using a digital camera andan ImageJ program and compared with each other.

As a result, as illustrated in FIGS. 9 and 10, it could be seen thatwhen peptide 1 or peptide 2 was treated, a reduction in wound sizesimilar to or better than a positive control was obtained. Inparticular, since peptide 2 has a twice larger molecular weight as adimeric form of peptide 1, even though the peptide 2 was treated at alower concentration than that of peptide 1, it could be seen that thepeptide 2 had an excellent effect as compared to the case treated withthe peptide 1 and the excellent wound treatment effect even compared toa positive control group.

6-2. Confirmation of Histological Change

An acute wound was induced in the same manner as in Example 6-1, and theskin tissue was cut on 5 day after the acute wound was induced toprepare tissue fragments. Thereafter, histological changes according topeptide treatment were observed by H&E staining and observing the H&Estaining by a microscope. Meanwhile, an EGF was used as a positivecontrol group.

As a result, as illustrated in FIG. 11, in the tissues treated withpeptide 1 and peptide 2, thicknesses of epidermis and dermis layers werelarger than those of a PBS negative control group like a positivecontrol group. In addition, epithelialization also actively progressed,and histological opinions related to wound healing or recovery wereconfirmed.

When summarizing the results, it can be seen that the peptides (peptide1 and peptide 2) of the present invention may remarkably accelerate thewound recovery rate and may be used as an active substance for woundhealing.

The aforementioned description of the present invention is to beexemplified, and it can be understood by those skilled in the art thatthe technical spirit or required features of the present invention canbe easily modified in other detailed forms without changing. Therefore,it should be understood that the above-described exemplary embodimentsare illustrative in all aspects and do not limit the present invention.

The invention claimed is:
 1. A synthetic peptide selected from the aminoacid sequence consisting of SEQ ID NO: 1 or the amino acid sequenceconsisting of SEQ ID NO: 2, wherein the N- or C-terminal of thesynthetic peptide is attached to a protective group selected from thegroup consisting of an acetyl group, a fluorenylmethoxy carbonyl group,a formyl group, a palmitoyl group, a myristyl group, a stearyl group, apolyethylene glycol (PEG) group, a methyl group, an amide group, analbumin group, a polysialic acid (PSA) group, a hydroxyethyl starch(HES) group, and a C12-C18 fatty acid group.
 2. A method for skinregeneration or wound healing, comprising the step of administering acomposition comprising a pharmaceutically effective amount of asynthetic peptide or a polynucleotide encoding the peptide as an activeingredient to a subject or subject having a wound, wherein the syntheticpeptide is selected from the amino acid sequence consisting of SEQ IDNO: 1 or SEQ ID NO:
 2. 3. The method of claim 2, wherein the N- orC-terminal of the synthetic peptide is attached to a protective groupselected from the group consisting of an acetyl group, afluorenylmethoxy carbonyl group, a formyl group, a palmitoyl group, amyristyl group, a stearyl group, or a polyethylene glycol (PEG) group, amethyl group, an amide group, an albumin group, a polysialic acid (PSA)group, a hydroxyethyl starch (HES) group, and a C12-C18 fatty acidgroup.
 4. The method of claim 2, wherein the peptide is contained at aconcentration of 1 to 500 ng/ml.
 5. The method of claim 2, wherein thewound is a gash.
 6. The method of claim 2, wherein the compositionfurther comprises a pharmaceutically acceptable carrier.
 7. A method forimproving skin aging or wound healing, comprising the step ofadministering a composition comprising a cosmetically effective amountof a synthetic peptide or a polynucleotide encoding the peptide as anactive ingredient to a subject or subject having a wound, wherein thesynthetic peptide is selected from the amino acid sequence consisting ofSEQ ID NO: 1 or SEQ ID NO:
 2. 8. The method of claim 7, wherein the N-or C-terminal of the synthetic peptide is attached to a protective groupselected from the group consisting of an acetyl group, afluorenylmethoxy carbonyl group, a formyl group, a palmitoyl group, amyristyl group, a stearyl group, or a polyethylene glycol (PEG) group, amethyl group, an amide group, an albumin group, a polysialic acid (PSA)group, a hydroxyethyl starch (HES) group, and a C12-C18 fatty acidgroup.
 9. The method of claim 7, wherein the composition is in the formof suspension, emulsion, paste, gel, cream, lotion, powder, wax orspray.
 10. The method of claim 7, wherein the composition has a skinwhitening activity.
 11. The synthetic peptide of claim 1, wherein theamino acid sequence consists of SEQ ID NO:
 1. 12. A synthetic peptidewith an amino acid sequence consisting of SEQ ID NO:
 2. 13. Apharmaceutical composition comprising a synthetic peptide with an aminoacid sequence consisting of SEQ ID NO: 2 and a pharmaceuticallyacceptable carrier.